• Users Online: 313
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 31  |  Issue : 3  |  Page : 382-384

Screening and management of statin cause a case of prediabetes in an outpatient clinic in Afghanistan: a case report in Andkhoy City

1 Centre for Rural Health, School of Health Sciences-University of Tasmania, Australia
2 Faculty of Stomatology, Kunduz University; Curative Clinic, Afghanistan
3 Arya University Faculty of Medicine, Mazar-i-Sharif; Curative Clinic, Afghanistan
4 Faculty of Dentistry, AbantIzzetBaysal University, Bolu, Turkey
5 Curative Clinic, Afghanistan

Correspondence Address:
Mohammad Shoaib Hamrah
Centre for Rural Health, School of Health Science University of Tasmania Locked Bag 1322, Launceston TAS 7250
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejim.ejim_109_18

Rights and Permissions

Dyslipidemia is known as an independent risk factor for cardiovascular disease. Recently, interest has been raised on the risk of new onset of diabetes mellitus with statin treatment. We report on a 41-year-old man with dyslipidemia. His blood tests at the time of admission showed that there was a rise in low-density lipoprotein levels (155 mg/dl), low high-density lipoprotein levels (34 mg/dl), normal triglyceride levels (82 mg/dl), normal fasting blood sugar levels (85 mg/dl), and normal glycated hemoglobin (HbA1c) (5.3%). Follow-up for about 2.5 years for statin use revealed that the patient’s lipid profile has improved; however, his HbA1c increased from 5.3 to 6.1%. The patient was prescribed Metformin and the statin was replaced with Ezetimibe. Little changes in blood HbA1c levels were observed at 1-year follow-up. Then, dipeptidyl peptidase-4 inhibitors, Sitagliptin, was introduced at 25 mg once per day, and Metformin was discontinued. One year later, the patient’s laboratory tests showed: low-density lipoprotein (77 mg/dl), high-density lipoprotein (33 mg/dl), triglycerides (108 mg/dl), and HbA1c (5.5%). This finding revealed that the dipeptidyl peptidase-4 inhibitor, Sitagliptin is more likely to be the successful drug for the treatment of prediabetes with statin therapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded104    
    Comments [Add]    

Recommend this journal